BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

887 related articles for article (PubMed ID: 26382841)

  • 1. Tauopathies as clinicopathological entities.
    Irwin DJ
    Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1(0 1):S29-33. PubMed ID: 26382841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Invited review: Neuropathology of tauopathies: principles and practice.
    Kovacs GG
    Neuropathol Appl Neurobiol; 2015 Feb; 41(1):3-23. PubMed ID: 25495175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration.
    Riku Y; Iwasaki Y; Ishigaki S; Akagi A; Hasegawa M; Nishioka K; Li Y; Riku M; Ikeuchi T; Fujioka Y; Miyahara H; Sone J; Hattori N; Yoshida M; Katsuno M; Sobue G
    Brain; 2022 Aug; 145(8):2769-2784. PubMed ID: 35274674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pick's complex and FTDP-17.
    Kertesz A
    Mov Disord; 2003 Sep; 18 Suppl 6():S57-62. PubMed ID: 14502657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The neuropathological spectrum of neurodegenerative tauopathies.
    Tolnay M; Probst A
    IUBMB Life; 2003 Jun; 55(6):299-305. PubMed ID: 12938731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies.
    Forrest SL; Kril JJ; Stevens CH; Kwok JB; Hallupp M; Kim WS; Huang Y; McGinley CV; Werka H; Kiernan MC; Götz J; Spillantini MG; Hodges JR; Ittner LM; Halliday GM
    Brain; 2018 Feb; 141(2):521-534. PubMed ID: 29253099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tauopathies.
    Kovacs GG
    Handb Clin Neurol; 2017; 145():355-368. PubMed ID: 28987182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neuropathology of tauopathy].
    Yoshida M
    Brain Nerve; 2013 Dec; 65(12):1445-58. PubMed ID: 24323931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct phosphorylation profiles of tau in brains of patients with different tauopathies.
    Samimi N; Sharma G; Kimura T; Matsubara T; Huo A; Chiba K; Saito Y; Murayama S; Akatsu H; Hashizume Y; Hasegawa M; Farjam M; Shahpasand K; Ando K; Hisanaga SI
    Neurobiol Aging; 2021 Dec; 108():72-79. PubMed ID: 34536819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease.
    Stancu IC; Ferraiolo M; Terwel D; Dewachter I
    Adv Exp Med Biol; 2019; 1184():145-166. PubMed ID: 32096036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular and regional vulnerability in frontotemporal tauopathies.
    Forrest SL; Kril JJ; Halliday GM
    Acta Neuropathol; 2019 Nov; 138(5):705-727. PubMed ID: 31203391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transgenic mouse models of tauopathies: prospects for animal models of Pick's disease.
    Lee VM; Trojanowski JQ
    Neurology; 2001 Jun; 56(11 Suppl 4):S26-30. PubMed ID: 11402147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine.
    Irwin DJ; Cairns NJ; Grossman M; McMillan CT; Lee EB; Van Deerlin VM; Lee VM; Trojanowski JQ
    Acta Neuropathol; 2015 Apr; 129(4):469-91. PubMed ID: 25549971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations causing neurodegenerative tauopathies.
    Goedert M; Jakes R
    Biochim Biophys Acta; 2005 Jan; 1739(2-3):240-50. PubMed ID: 15615642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tau exhibits unique seeding properties in globular glial tauopathy.
    Chung DC; Carlomagno Y; Cook CN; Jansen-West K; Daughrity L; Lewis-Tuffin LJ; Castanedes-Casey M; DeTure M; Dickson DW; Petrucelli L
    Acta Neuropathol Commun; 2019 Mar; 7(1):36. PubMed ID: 30845985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel triple repeat mutant tau transgenic model that mimics aspects of pick's disease and fronto-temporal tauopathies.
    Rockenstein E; Overk CR; Ubhi K; Mante M; Patrick C; Adame A; Bisquert A; Trejo-Morales M; Spencer B; Masliah E
    PLoS One; 2015; 10(3):e0121570. PubMed ID: 25803611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and pathological heterogeneity of primary tauopathies.
    Chung DC; Roemer S; Petrucelli L; Dickson DW
    Mol Neurodegener; 2021 Aug; 16(1):57. PubMed ID: 34425874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tau Protein and Frontotemporal Dementias.
    Goedert M; Spillantini MG; Falcon B; Zhang W; Newell KL; Hasegawa M; Scheres SHW; Ghetti B
    Adv Exp Med Biol; 2021; 1281():177-199. PubMed ID: 33433876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau.
    Williams DR
    Intern Med J; 2006 Oct; 36(10):652-60. PubMed ID: 16958643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific post-translational modifications of soluble tau protein distinguishes Alzheimer's disease and primary tauopathies.
    Kyalu Ngoie Zola N; Balty C; Pyr Dit Ruys S; Vanparys AAT; Huyghe NDG; Herinckx G; Johanns M; Boyer E; Kienlen-Campard P; Rider MH; Vertommen D; Hanseeuw BJ
    Nat Commun; 2023 Jun; 14(1):3706. PubMed ID: 37349319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.